A low percentage of metastases in deep brain and temporal lobe structures.

abstract：:Allergies and the use of anti-inflammatory medication appear to be associated with reduced glioblastoma risk. However, these observations may merely reflect systemic immunosuppression induced by the tumor. To better understand the effect of this tumor on allergies and inflammation, we used CD133 mRNA expression as an ...

journal_title：Neuro-oncology

authors： Schwartzbaum JA,Huang K,Lawler S,Ding B,Yu J,Chiocca EA

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:Anaplastic oligodendroglial tumors are rare, and median survival varies widely. Analysis of 1p19q deletion is performed commonly and is an important prognostic factor. However, age and other clinical variables also carry prognostic value, and it is unclear how to incorporate them into clinical decision makin...

journal_title：Neuro-oncology

authors： Panageas KS,Reiner AS,Iwamoto FM,Cloughesy TF,Aldape KD,Rivera AL,Eichler AF,Louis DN,Paleologos NA,Fisher BJ,Ashby LS,Cairncross JG,Urgoiti GB,Wen PY,Ligon KL,Schiff D,Robins HI,Rocque BG,Chamberlain MC,Mason WP,

更新日期：2014-11-01 00:00:00

abstract：:In order to compare in vivo metabolism between malignant gliomas and normal brain, (13)C magnetic resonance (MR) spectroscopic imaging data were acquired from rats with human glioblastoma xenografts (U-251 MG and U-87 MG) and normal rats, following injection of hyperpolarized [1-(13)C]-pyruvate. The median signal-to-n...

journal_title：Neuro-oncology

authors： Park I,Larson PE,Zierhut ML,Hu S,Bok R,Ozawa T,Kurhanewicz J,Vigneron DB,Vandenberg SR,James CD,Nelson SJ

更新日期：2010-02-01 00:00:00

abstract：:Paragangliomas are rare tumors of the paraganglia composed of specialized neural crest cells arising in association with sympathetic ganglia. Here we report a case of progressive, metastatic paraganglioma (glomus jugulare tumor) responsive to single agent gemcitabine. In addition, a brief review of chemotherapy for pa...

journal_title：Neuro-oncology

authors： Pipas JM,Krywicki RF

更新日期：2000-07-01 00:00:00

abstract：Background:Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the diagnostic accuracy of 2HG single-voxel spectroscopy (SVS) and chemical shift imaging (CSI) in both newly diagnosed and posttreatment settings. Methods...

journal_title：Neuro-oncology

authors： Zhou M,Zhou Y,Liao H,Rowland BC,Kong X,Arvold ND,Reardon DA,Wen PY,Lin AP,Huang RY

更新日期：2018-08-02 00:00:00

abstract：BACKGROUND:Isocitrate dehydrogenase (IDH) mutation status has emerged as an important prognostic marker in gliomas. Currently, reliable IDH mutation determination requires invasive surgical procedures. The purpose of this study was to develop a highly accurate, MRI-based, voxelwise deep-learning IDH classification netw...

journal_title：Neuro-oncology

authors： Bangalore Yogananda CG,Shah BR,Vejdani-Jahromi M,Nalawade SS,Murugesan GK,Yu FF,Pinho MC,Wagner BC,Mickey B,Patel TR,Fei B,Madhuranthakam AJ,Maldjian JA

更新日期：2020-03-05 00:00:00

abstract：BACKGROUND:Temporal muscle thickness (TMT) was described as a surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma. METHODS:TMT was analyzed on cranial MR images of 596 patients with progression of glioblastoma after radiochemo...

journal_title：Neuro-oncology

authors： Furtner J,Genbrugge E,Gorlia T,Bendszus M,Nowosielski M,Golfinopoulos V,Weller M,van den Bent MJ,Wick W,Preusser M

更新日期：2019-12-17 00:00:00

abstract：:We examined DNA damage responses and repair in four human glioma cell lines (A7, U87, T98G, and U373) and normal human astrocytes (NHAs) after clinically relevant radiation doses to establish whether we could identify differences among them that might suggest new approaches to selective radiosensitization. We used pho...

journal_title：Neuro-oncology

authors： Short SC,Martindale C,Bourne S,Brand G,Woodcock M,Johnston P

更新日期：2007-10-01 00:00:00

abstract：:Diffuse low-grade glioma grows, migrates along white matter tracts, and progresses to high-grade glioma. Rather than a "wait and see" policy, an aggressive attitude is now recommended, with early surgery as the first therapy. Intraoperative mapping, with maximal resection according to functional boundaries, is associa...

journal_title：Neuro-oncology

authors： Duffau H,Taillandier L

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or Temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of radiotherapy on memory functioning, this stu...

journal_title：Neuro-oncology

authors： Klein M,Drijver AJ,van den Bent MJ,Bromberg JC,Hoang-Xuan K,Taphoorn MJB,Reijneveld JC,Ben Hassel M,Vauleon E,Eekers DBP,Tzuk-Shina T,Lucas A,Freixa SV,Golfinopoulos V,Gorlia T,Hottinger AF,Stupp R,Baumert BG

更新日期：2020-11-01 00:00:00

abstract：:Vestibular schwannomas (VS) arising sporadically or in patients with neurofibromatosis type 2 (NF2) consistently lack expression of Merlin, a tumor suppressor. Conventional treatment options include surgery and radiotherapy but there is no validated medical option. Recent evidence suggests that Merlin deficiency may r...

journal_title：Neuro-oncology

authors： Ammoun S,Cunliffe CH,Allen JC,Chiriboga L,Giancotti FG,Zagzag D,Hanemann CO,Karajannis MA

更新日期：2010-08-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777...

journal_title：Neuro-oncology

authors： Lustig R,Mikkelsen T,Lesser G,Grossman S,Ye X,Desideri S,Fisher J,Wright J,New Approaches to Brain Tumor Therapy CNS Consortium.

更新日期：2008-12-01 00:00:00

abstract：BACKGROUND:Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular s...

journal_title：Neuro-oncology

authors： Eckel-Passow JE,Drucker KL,Kollmeyer TM,Kosel ML,Decker PA,Molinaro AM,Rice T,Praska CE,Clark L,Caron A,Abyzov A,Batzler A,Song JS,Pekmezci M,Hansen HM,McCoy LS,Bracci PM,Wiemels J,Wiencke JK,Francis S,Burns TC,

更新日期：2020-11-26 00:00:00

abstract：:The Atlas of Cancer Mortality in the United States, 1950-94 (Devesa et al.) published in 1999 by the National Institutes of Health suggests that there are elevated rates of brain and other nervous system cancer in the northwestern, north central, and southeastern parts of the country. Being descriptive in nature, the ...

journal_title：Neuro-oncology

authors： Fang Z,Kulldorff M,Gregorio DI

更新日期：2004-07-01 00:00:00

abstract：:We explored the associations of aberrant DNA methylation patterns in 12 candidate genes with adult glioma subtype, patient survival, and gene expression of enhancer of zeste human homolog 2 (EZH2) and insulin-like growth factor-binding protein 2 (IGFBP2). We analyzed 154 primary glioma tumors (37 astrocytoma II and II...

journal_title：Neuro-oncology

authors： Zheng S,Houseman EA,Morrison Z,Wrensch MR,Patoka JS,Ramos C,Haas-Kogan DA,McBride S,Marsit CJ,Christensen BC,Nelson HH,Stokoe D,Wiemels JL,Chang SM,Prados MD,Tihan T,Vandenberg SR,Kelsey KT,Berger MS,Wiencke JK

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Glioblastoma multiforme (GBM) is characterized by an aggressive clinical course, therapeutic resistance, and striking molecular heterogeneity. GBM-derived brain tumor stem cells (BTSCs) closely model this molecular heterogeneity and likely have a key role in tumor recurrence and therapeutic resistance. Emerg...

journal_title：Neuro-oncology

authors： Stechishin OD,Luchman HA,Ruan Y,Blough MD,Nguyen SA,Kelly JJ,Cairncross JG,Weiss S

更新日期：2013-02-01 00:00:00

abstract：:Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...

journal_title：Neuro-oncology

authors： Meyers CA,Hess KR

更新日期：2003-04-01 00:00:00

abstract：:As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in...

journal_title：Neuro-oncology

authors： Dunn GP,Cloughesy TF,Maus MV,Prins RM,Reardon DA,Sonabend AM

更新日期：2020-10-14 00:00:00

abstract：BACKGROUND:This study aimed to evaluate the prognostic significance of co-polsomy of chromosome 1q and 19p in 1p/19q codeleted oligodendroglial tumors (ODGs). METHODS:In a series of 148 ODGs with 1p/19q deletion, co-polysomy of 1q and 19p was detected by fluorescence in situ hybridization (FISH). Log-rank analysis and...

journal_title：Neuro-oncology

authors： Ren X,Jiang H,Cui X,Cui Y,Ma J,Jiang Z,Sui D,Lin S

更新日期：2013-09-01 00:00:00

abstract：:Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by...

journal_title：Neuro-oncology

authors： Wu J,Armstrong TS,Gilbert MR

更新日期：2016-07-01 00:00:00

abstract：Background:Molecular profile of glioblastoma multiforme (GBM) revealed 4 subtypes, 2 of which, proneural and mesenchymal, have been predominantly observed, with the latter displaying a more aggressive phenotype and increased therapeutic resistance. Single-cell RNA sequencing revealed that multiple subtypes actually res...

journal_title：Neuro-oncology

authors： Teng J,da Hora CC,Kantar RS,Nakano I,Wakimoto H,Batchelor TT,Chiocca EA,Badr CE,Tannous BA

更新日期：2017-06-01 00:00:00

abstract：:The signaling pathways that underlie the pathogenesis of pediatric gliomas are poorly understood. We characterized the PI3K/Akt/mTOR pathway in pediatric gliomas of all grades. Using immunohistochemistry, we assessed activation of the PI3K/Akt/mTOR pathway by evaluating the downstream signaling molecules phospho(p)-S6...

journal_title：Neuro-oncology

authors： Mueller S,Phillips J,Onar-Thomas A,Romero E,Zheng S,Wiencke JK,McBride SM,Cowdrey C,Prados MD,Weiss WA,Berger MS,Gupta N,Haas-Kogan DA

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:The colony stimulating factor 1 receptor (CSF1R) ligands, CSF1 and interleukin-34, and the KIT ligand, stem cell factor, are expressed in glioblastoma (GB). Microglia, macrophages, blood vessels, and tumor cells also express CSF1R, and depletion of the microglia reduces tumor burden and invasive capacity. PL...

journal_title：Neuro-oncology

authors： Butowski N,Colman H,De Groot JF,Omuro AM,Nayak L,Wen PY,Cloughesy TF,Marimuthu A,Haidar S,Perry A,Huse J,Phillips J,West BL,Nolop KB,Hsu HH,Ligon KL,Molinaro AM,Prados M

更新日期：2016-04-01 00:00:00

abstract：Background:There have been few treatment advances for patients with glioblastoma (GBM) despite increasing scientific understanding of the disease. While factors such as intrinsic tumor biology and drug delivery are challenges to developing efficacious therapies, it is unclear whether the current clinical trial landscap...

journal_title：Neuro-oncology

authors： Vanderbeek AM,Rahman R,Fell G,Ventz S,Chen T,Redd R,Parmigiani G,Cloughesy TF,Wen PY,Trippa L,Alexander BM

更新日期：2018-07-05 00:00:00

abstract：BACKGROUND:No reliable estimates are available on the incidence of brain metastasis (BM) in cancer patients. This information is valuable for planning patient care and developing measures that may prevent or decrease the likelihood of metastatic brain disease. METHODS:We report the first population-based analysis on B...

journal_title：Neuro-oncology

authors： Villano JL,Durbin EB,Normandeau C,Thakkar JP,Moirangthem V,Davis FG

更新日期：2015-01-01 00:00:00

abstract：Background:Targeted approaches for treating glioblastoma (GBM) attempted to date have consistently failed, highlighting the imperative for treatment strategies that operate on different mechanistic principles. Bioenergetics deprivation has emerged as an effective therapeutic approach for various tumors. We have previou...

journal_title：Neuro-oncology

authors： Park J,Shim JK,Kang JH,Choi J,Chang JH,Kim SY,Kang SG

更新日期：2018-06-18 00:00:00

abstract：BACKGROUND:The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but t...

journal_title：Neuro-oncology

authors： de la Fuente MI,Young RJ,Rubel J,Rosenblum M,Tisnado J,Briggs S,Arevalo-Perez J,Cross JR,Campos C,Straley K,Zhu D,Dong C,Thomas A,Omuro AA,Nolan CP,Pentsova E,Kaley TJ,Oh JH,Noeske R,Maher E,Choi C,Gutin PH,Ho

更新日期：2016-02-01 00:00:00

abstract：BACKGROUND:We assessed the longitudinal hazard characteristics for death and progression in patients with glioblastoma, evaluated the impact of prognostic factors and treatment on the hazard within different time intervals to determine if effects are time varying, and quantified the influence of progression on survival...

journal_title：Neuro-oncology

authors： Wang M,Dignam JJ,Won M,Curran W,Mehta M,Gilbert MR

更新日期：2015-07-01 00:00:00

abstract：:Gliomas are a heterogeneous group of brain tumors with distinct biological and clinical properties. Despite advances in surgical techniques and clinical regimens, treatment of high-grade glioma remains challenging and carries dismal rates of therapeutic success and overall survival. Challenges include the molecular co...

journal_title：Neuro-oncology

authors： Malta TM,de Souza CF,Sabedot TS,Silva TC,Mosella MS,Kalkanis SN,Snyder J,Castro AVB,Noushmehr H

更新日期：2018-04-09 00:00:00

abstract：:The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have led to better systemic control and longer overall patient survi...

journal_title：Neuro-oncology

authors： Arvold ND,Lee EQ,Mehta MP,Margolin K,Alexander BM,Lin NU,Anders CK,Soffietti R,Camidge DR,Vogelbaum MA,Dunn IF,Wen PY

更新日期：2016-08-01 00:00:00